NRx Pharmaceuticals (NRXP) CEO to Provide Business Update on January 10th
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
NRx Pharmaceuticals (NRXP) to Present New Details for Planned Investigational BriLife COVID-19 Vaccine
January 10, 2022 5:56 AM ESTNRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today announced its Chairman of the Board and Chief Executive Officer, Prof Jonathan Javitt, MD, MPH, will be presenting updates to the Companys business, including new details regarding late-stage trials of the investigational BriLife COVID-19 vaccine at the H.C. Wainwright BioConnect... More
NRx Pharmaceuticals (NRXP) Submits EUA with FDA for ZYESAMI to Treat Patients at Immediate Risk of Death from COVID-19
January 5, 2022 6:50 AM ESTNRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has submitted an application for Emergency Use Authorization (EUA) to the US Food and Drug Administration (FDA) for the use of ZYESAMI® (aviptadil) in patients with Critical COVID-19 who are at immediate risk of death from Respiratory Failure despite treatment with approved therapy including remdesivir and who are ineligible for enrollment into the ongoing ACTIV-3b NIH-sponsored trial..
"We appreciate the detailed feedback and learnings from our previous EUA submission, and applied them to this narrower request to the FDA," said Prof Jonathan Javitt, MD,... More
